Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Altitude pill may also fight inflammation, early study hints

NCT ID NCT07517068

Knowledge-focused Sponsor: University of California, Riverside Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether acetazolamide, a drug already used for altitude sickness, can reduce inflammation and immune system activation caused by high altitude. Nineteen healthy adults will take either the drug or a placebo before and during a stay at 3800 meters. Researchers will measure changes in immune cells and inflammatory markers in the blood.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Acetazolamide
What this could lead to
If successful, this could help explain how acetazolamide prevents altitude sickness and may point to new ways to control inflammation.
What could go wrong
This is a very small, early-phase study (19 people) looking at blood markers, not symptoms. Results may not apply to the general public or lead to a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

19 people

The number who actually took part.

Started

Sep 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

This study will include men and women who meet the following inclusion criteria: * Between ages 18 and 65 * No history of cardiovascular or pulmonary disease (previously diagnosed or indicated by EKG, spirometry, and other medical history) * No history of high altitude pulmonary or cerebral edema (HAPE or HACE) * No history of obstructive or central sleep apnea * No current use of anti-inflammatory medication, steroids, stimulants, or other agents that may interfere with ventilatory chemosensitivity * No current pregnancy * No travel above 8,000 feet elevation within 1 month of the first measures * Non-smokers (including any type of vape use, marijuana usage) * No current or recently treated systemic or serious local infection * Must be fluent in the English language * Participants must refrain from consuming alcohol for at least 1 week prior to the start of the study, throughout the duration of their participation, and for 2 days prior to their follow-up visits. * Caffeine and other stimulants may not be consumed during the course of participation in the high-altitude portion of the study (including 12 hours before sea level baseline measures, then starting 2 days before ascent and ending upon return to sea level). * Strenuous physical activity including hiking to higher elevations is not permitted during the high altitude portion of the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute mountain sickness (AMS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute mountain sickness altitude sickness Hypoxia Inflammation inflammatory disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute mountain sickness (AMS) Hypoxemia Immune response Inflammation

Contacts and locations

Locations

  • University of California, Riverside

    Riverside, California, 92521, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.